This study investigates the association of the rs4646994 polymorphism in the ACE1 gene with the severity of COVID-19 in children from Ukraine. The research focused on the potential genetic predisposition to severe COVID-19, specifically examining how the I/D polymorphism in the ACE1 gene might influence disease severity and lung damage. The study involved 244 children with confirmed COVID-19, and genotyping was performed using melting curve analysis of PCR products. The results demonstrated a significant association between the I allele (both homozygous and heterozygous) and more severe disease outcomes, particularly lung injury. These findings suggest that the ACE1 gene polymorphism may serve as a genetic marker for predicting disease severity and guiding personalized treatment for children with COVID-19.
Takeaways:
- The study highlights the importance of genetic factors, particularly the ACE1 gene polymorphism, in determining the severity of COVID-19 in children.
- The rs4646994 polymorphism in the ACE1 gene is associated with more severe disease and lung damage in children infected with COVID-19.
- The findings suggest that genetic testing for the ACE1 polymorphism could help predict the course of COVID-19 in pediatric patients.
- The study supports the potential use of ACE1 polymorphism as a marker for personalized treatment strategies in COVID-19.
- The research provides a foundation for future studies to investigate genetic predispositions in other populations and age groups.
